Advancing AAV Gene Therapy: Integrated CMC Strategy for the New Era of Scalable Manufacturing

Introduction

Adeno-associated virus (AAV) has become one of the most important delivery platforms in gene therapy, valued for its favorable safety profile, broad tissue tropism, and ability to enable durable transgene expression in both dividing and non-dividing cells. Clinical approvals for products treating inherited retinal dystrophies, spinal muscular atrophy, and hemophilia have validated AAV’s therapeutic potential and paved the way for a robust pipeline of investigational products targeting a wide array of indications. However, as the field transitions from pioneering academic research to commercial reality, a fundamental shift is occurring. The core question is no longer only whether an AAV candidate can show biological promise. Increasingly, success depends on whether that candidate can be translated into a product that is reproducible, analytically characterized, scalable, and acceptable from a Chemistry, Manufacturing, and Controls (CMC) and regulatory standpoint. The bottleneck is moving from proof of concept to proof of manufacturability.

AAV manufacturing remains time-consuming and high-risk because the field still lacks mature standards, robust large-scale platforms, and faster, more informative analytics. Doses often reach 10¹³–10¹⁴ vector genomes per patient, demanding reproducible yields that exceed the practical limits of many legacy methods while preserving critical quality attributes such as full capsid content, genome integrity, and potency. Large-scale production, formulation, and long-term stability remain major bottlenecks despite the modality’s clinical promise. Upstream variability in transfection efficiency, cell density at harvest, and helper-virus or plasmid ratios frequently introduces heterogeneous particle populations, including empty capsids, partially packaged genomes, and aggregates—while downstream recovery suffers from shear sensitivity, non-specific adsorption, and incomplete separation of product-related impurities. These issues compound into elevated cost-of-goods, extended-release timelines, and comparability risks that have stalled multiple programs at the IND-to-BLA transition. Scalable process steps, quality systems, and stage-appropriate controls must be built in early if a program is going to progress cleanly through development.

The Foundation of CMC Success: Defining the Product and Embracing QbD

The first major challenge is that many AAV programs still begin process work before the product profile is fully defined. Route of administration, dose range, capsid choice, transgene cassette design, potency expectations, and impurity tolerance all influence what the manufacturing process and control strategy should look like. When those questions are left unresolved, teams often end up trying to retrofit analytics and specifications onto a process that was never designed around the product’s clinical use. That creates avoidable CMC friction later.

A successful AAV program therefore begins not at the lab bench, but with a clear definition of the final product. Defining the Quality Target Product Profile (QTPP) and identifying the Critical Quality Attributes (CQAs) early is paramount. These elements directly inform the design of a manufacturable and controllable process. A failure to prospectively link product characteristics to process capabilities is a primary cause of late-stage CMC failures, where programs find themselves attempting to retrofit analytical methods and specifications onto a process never designed for commercial reality.

This is where a Quality by Design (QbD) framework becomes indispensable. QbD is a systematic approach that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. For AAV, this means moving beyond simply maximizing yield to establish a design space where process parameters are linked to their impact on CQAs, such as the full-to-empty capsid ratio, potency, and genome integrity. Implementing QbD requires rigorous process characterization using validated scale-down models (SDMs). These models, which can represent unit operations from bioreactors to chromatography columns, allow for the systematic exploration of process parameters through Design of Experiments (DoE), enabling the identification of Critical Process Parameters (CPPs) and the establishment of Proven Acceptable Ranges (PARs) and Normal Operating Ranges (NORs). This data-driven approach not only builds process robustness but also serves as the bedrock for a compelling regulatory submission. The overall CMC strategy is shown in figure 1.

Vector Design as a Manufacturing Variable

The second challenge is that vector design itself is a manufacturing variable. Genome size, ITR integrity, regulatory elements, and cassette architecture can directly affect packaging efficiency, genome integrity, heterogeneity, and consistency. AAV products routinely include not only desired full capsids, but also partial genomes, empty particles, aggregates, and mis-packaged DNA. Classic work has shown that when plasmid-encoded genomes exceed the practical packaging limit of approximately 4.7 kb, packaged genomes can become heterogeneous and 5′ truncated rather than fully intact. That means construct design cannot sit only with discovery biology; it must be reviewed through a manufacturability lens from the start, jointly by vector design, analytical, and process teams.

Raw Materials and Starting Materials: The Foundation of Consistency

Raw materials and starting materials are another persistent pressure point, especially in transient transfection systems that remain widely used for AAV production. Plasmid quality, identity, supercoiled content, endotoxin burden, traceability, and supply continuity can all influence yield and quality attributes. Supercoiled percentage (SC%) is particularly critical, as high SC% facilitates more compact complex formation with transfection reagents and enhances cellular uptake, directly impacting transfection efficiency and vector productivity. Raw material qualification, documentation, quality systems, and change control are foundational—not optional add-ons once a program reaches a later stage. The practical lesson is clear: do not let “plasmids are just starting materials” become a hidden source of batch variability.

Upstream Processing: From Plasmid to Potency

Upstream development adds another layer of complexity because AAV manufacturing is highly interconnected. Upstream choices affect not only vector genome yield, but also impurity burden, capsid composition, and downstream recoverability. The most common production method for clinical material, transient transfection of HEK293 cells, relies heavily on the quality of plasmid DNA, but achieving efficient delivery of multiple plasmids to every cell is difficult, often leading to variable vector titers and inconsistent ratios of full to empty capsids.

Furthermore, the choice between adherent and suspension cultures presents a scalability trade-off. Adherent systems, while simple to implement, rely on a scale-out approach that is operationally cumbersome and costly for late-stage manufacturing. Suspension cultures offer a path to true volumetric scale-up in stirred-tank bioreactors but can suffer from lower cell densities and transfection efficiencies. To address this, recent innovations in upstream processing are moving toward high-cell-density perfusion cultures and novel plasmid systems, such as streamlined dual-plasmid systems, which consolidate genetic elements to improve transfection efficiency and reduce batch variability. The field consistently describes AAV manufacturing as a system where process choices influence impurity profiles and product heterogeneity—not just output titer. Best practice therefore requires defining CPPs linked to specific CQAs, especially full/empty/intermediate capsid distribution, aggregation, residual host-cell DNA and protein, genome integrity, and potency drift.

Downstream Bottlenecks: The Quest for Purity and the Full Capsid

Downstream processing (DSP) is arguably where the greatest AAV manufacturing challenges converge and where many programs “discover” their real product in terms of purity, capsid composition, recovery, scalability, and comparability risk. The objective is to isolate intact, functional viral particles from a complex mixture of host cell proteins (HCPs), host cell DNA (HCD), plasmid DNA, and process-related impurities, while simultaneously separating product-related impurities like empty and partially filled capsids from the therapeutic, genome-containing vectors. This is a formidable task, as these species are physicochemically similar.

Traditional purification methods like cesium chloride (CsCl) density gradient ultracentrifugation, while effective at separating full and empty capsids, are time-consuming and tedious. The industry has therefore pivoted to chromatography-based methods. Affinity chromatography provides excellent capture and purification from bulk impurities but is serotype-dependent and cannot distinguish between full and empty capsids. The critical polishing step, typically anion exchange chromatography (AEX), leverages the subtle difference in surface charge between empty and DNA-filled capsids. However, resolving these populations is challenging and requires highly optimized conditions. A recurring CMC challenge is that “full/empty” is not binary—intermediate and partially filled capsids matter and can complicate interpretation across methods. The presence of partially filled or intermediate capsids further complicates separation and requires orthogonal analytical methods for accurate quantification. Practical advice dictates developing DSP with a predefined analytical panel that can distinguish empty versus partially packaged versus full capsids, aggregates, damaged capsids, and genome truncation. If you only track vg and capsid titer, you may miss the real process signal.

The Analytical Heartbeat: Characterizing a Complex Modality

AAV analytics is the central nervous system of the entire manufacturing operation; without robust, reliable assays, process development is blind and product quality is unprovable. The required analytical package is extensive, covering identity, purity, safety, and potency. However, current analytical methods for AAV are often time-consuming, low-throughput, and lack the resolution needed for this complex molecule. Analytical standardization involves testing the breadth of rAAV product-related impurities and the need to standardize characterization approaches and CQAs. It also notes potency complexity and the need for more versatile potency assays due to transgene and serotype dependence.

For instance, quantifying the empty/full/intermediate capsid distribution demands orthogonal methods like Analytical Ultracentrifugation (AUC) and the emerging method, Mass Photometry (MP), which offers single-particle resolution to distinguish partially filled species missed by other techniques. Similarly, genome integrity, a critical attribute, requires methods beyond simple titer determination, such as capillary electrophoresis (CE) or next-generation sequencing (NGS) to detect truncations or rearrangements. No single method fully describes AAV; orthogonal methods are essential.

The greatest analytical challenge, however, remains the potency assay. Regulatory guidance, including recent FDA drafts, explicitly calls for a matrix approach that goes beyond a single test. The FDA’s potency assurance draft guidance (2023) specifically describes potency assurance as a science- and risk-based strategy spanning process design, controls, in-process testing, and lot release—not merely a final assay. A robust potency strategy should link a mechanism-of-action (MoA)-relevant functional bioassay with supporting data from infectivity (e.g., TCID50) and expression assays. Reliance on genomic titer as a surrogate for potency is a common pitfall that leads to clinical holds. What strong potency programs do: define MoA-relevant potency (or a justified surrogate if early phase), use matrix potency models (e.g., physical titer + infectivity + expression/activity), trend potency versus CQAs over time, include reference standards and control materials, and predefine assay evolution plans from Phase 1 to BLA.

The Final Frontier: Formulation, Fill-Finish, and Comparability

The challenges of AAV extend into the final steps of the manufacturing process. Formulation is critical for ensuring the vector remains stable and efficacious throughout storage, shipping, and administration. Many “good” AAV drug substances degrade into problematic drug products due to formulation and handling issues. The physical and chemical instabilities of AAV capsids are well-documented. Physical instabilities include aggregation, often triggered by low ionic strength, freeze-thaw cycles, or shear stress during fill/finish operations. Surface adsorption to containers and administration devices can lead to significant dose loss, a problem elegantly solved by the inclusion of non-ionic surfactants like poloxamer 188 in the formulation buffer. Chemical instabilities, such as deamidation and oxidation of amino acid residues on the capsid surface, can alter vector function and charge heterogeneity over time, impacting long-term stability. Formulation and stability are the major translational bottlenecks, especially given capsid sensitivity and multiple degradation pathways. The practical rule is to run forced-degradation and stress studies early to understand what your assays can detect.

Finally, the concept of comparability underpins the entire product lifecycle and is becoming a program-defining capability. Most AAV programs will change something: plasmid source, transfection reagent, scale, chromatography resin, facility or site, analytical method, formulation, or fill line. If you don’t plan comparability early, development speed becomes a liability. FDA’s 2023 draft comparability guidance for CGT products emphasizes lifecycle management and comparability studies to assess manufacturing change impact on product quality. What to implement now: a comparability protocol mindset (even if informal pre-IND), retain representative lots and samples, use a stable reference material strategy, trend critical assays longitudinally, and predefine tiered responses to change (minor, moderate, major).

Figure 1. AAV gene therapy CMC strategic framework

PackGene’s Integrated Solution: A Platform Approach to De-risk AAV CMC

Navigating the complexities of AAV CMC requires a partner with deep expertise and an integrated platform. A recurring weakness across the AAV field is fragmentation: vector design, process development, analytics, GMP manufacturing, and release testing are often handled as separate activities. PackGene’s model is built to connect those functions through an integrated, end-to-end workflow spanning process development, analytical development, GMP plasmid supply, GMP AAV manufacturing, and batch release testing. This offering is designed to support programs from preclinical development through clinical manufacturing and commercial supply, with integrated support for process optimization, assay development, GMP production, fill and finish, comparability, stability, and release documentation. Instead of treating manufacturing steps as isolated events, our approach is built on a platform philosophy that prioritizes scalability, analytical control, and regulatory readiness from day one.

1. A) Platform Manufacturing and Tech Transfer: Embedding Scalability

PackGene’s GMP manufacturing platform is purpose-built for scalability and rapid tech transfer. Moving away from adherent systems, the platform leverages scalable suspension technologies, enabling a direct and predictable path from process development to large-scale GMP production. Our GMP AAV manufacturing capability is built with a high-productivity, scalable platform supported by in-house GMP plasmid manufacturing, comprehensive release testing, and rapid progression toward clinical application. Support extends from pilot to commercial scale, including campaigns from 25 L up to 2,000 L, supported by dedicated GMP vector suites, GMP plasmid suites, and extensive in-house AAV analytical methods for QC and lot release. This approach mitigates the risk of late-stage process changes and comparability crises. By utilizing a structured onboarding and tech transfer protocol, we ensure that a client’s product-specific knowledge is seamlessly integrated into a robust, GMP-ready process. This platform leverage translates to faster entry into the clinic and a more efficient path to commercialization, ensuring that process development decisions are always aligned with a clear filing strategy and future commercial viability.

PackGene’s process development capabilities reinforce that positioning. Our process development services use data-driven DoE, tailored upstream, purification, and formulation workflows, seamless GMP scale-up, and IND-ready documentation in electronic lab notebooks. Proprietary helper plasmid support and a focus on building cost-effective, optimized processes for both plasmid and AAV production tie development work more directly to later GMP execution instead of treating scale-up as a separate exercise (Figure 2).

Figure 2. AAV process development and scale up

1. B) CQA-Driven Analytical Development: The Power of Orthogonal Data

Recognizing that analytics are the heart of CMC, PackGene has built a best-in-class analytical development capability guided by a CQA-focused, QbD-based design. Our AAV analytical development platform emphasizes comprehensive testing for identity, purity, potency, and safety, along with custom assay development, validated phase-appropriate methods, predefined release criteria, and fast turnaround for GMP-grade QC and release support. QC coverage extends from raw materials through final AAV product, which fits well with a lifecycle-oriented CMC narrative and supports the broader point that analytics are central to process understanding, release confidence, and regulatory readiness.

The extensive assay menu goes beyond standard release testing to provide the deep characterization needed for true process understanding. This includes orthogonal methods for quantifying full, empty, and intermediate capsids (e.g., AUC, Mass Photometry), assessing genome integrity (e.g., CE, NGS), and profiling capsid proteins (e.g., peptide mapping, CE-SDS). By linking process development decisions—such as harvest timing or polishing conditions—directly to shifts in these high-resolution CQAs, we provide clients with an unparalleled understanding of their product and process. This data-rich environment not only drives robust process development but also builds the strong analytical dossier required for IND and BLA filings.

1. C) Integrated Release Testing: Accelerating Timelines and Reducing Risk

The “Make-and-Test” workflow is a core tenet of PackGene’s service model, integrating GMP manufacturing with in-house batch release testing. Our release-testing workflow is co-located to reduce delays and risks associated with external testing, while supporting identity, potency, purity, and safety testing under ICH Q2(R1) standards and FDA/EMA-aligned expectations. With over 60 assays qualified and validated according to ICH guidelines, covering safety (sterility, endotoxin, mycoplasma, rcAAV, subvisible particles), identity (genome and capsid), purity (SEC-HPLC, CE-SDS), and strength (ddPCR, TCID50), we provide a complete, cohesive data package for each lot, accompanied by a fully audited Certificate of Analysis.

This integration collapses timelines by eliminating the logistical delays and communication gaps associated with fragmented outsourcing to different labs. End-to-end responsibility ensures that manufacturing and QC data are perfectly aligned, significantly improving lot release predictability and providing a solid foundation for executing robust comparability protocols when process changes are necessary.

1. D) In-House GMP Plasmid Manufacturing: Securing the Foundation

PackGene’s in-house GMP plasmid manufacturing capability is another meaningful advantage because plasmids are a foundational starting material for many transient transfection-based AAV programs. PackGene’s proprietary π-Omega Plasmid DNA High-yield Platform increases plasmid yield by more than 3 times through plasmid backbone modifications. Production scale can reach up to 200L, and single-batch production yields can reach up to 100 grams (figure 3). As a key raw material in AAV production, plasmid DNA cost reduction greatly reduces AAV production cost. The platform uses isolated production lines and single-use technology with bacteria banking and scalable process development. In-house QC testing is used for identity, purity, potency, residuals, and endotoxin measurement. Bringing plasmid production into the broader AAV manufacturing workflow helps support traceability, raw material consistency, and supply continuity—areas that are often underestimated until variability begins to affect vector output or comparability.

Figure 3. PackGene’s proprietary π-Omega plasmid DNA high-yield platform

1. E) A Partnership for Lifecycle

Ultimately, we are not just as a service provider, but as an extension of a client’s team, committed to cost-effective and scalable outcomes. This partnership is framed in practical CMC terms: improving yield recovery, reducing batch failure risk through robust process characterization, minimizing delays with integrated analytics, and building a scalable process architecture that de-risks future comparability. We not only manufacture AAV, but can help clients move from promising vector candidates to more controlled, scalable, and regulator-ready products through integrated CMC execution. By integrating CMC strategy, analytical science, and GMP manufacturing from day one, we empower AAV developers to navigate the “CMC cliff” with confidence, ensuring that promising science can be translated into accessible, life-changing gene therapies for patients.

Why This Matters Now

The AAV field is entering a phase where industrialization matters as much as innovation. The biggest risks in the field now come from disconnected development: vector design without manufacturability review, process development without analytical depth, purification without orthogonal characterization, or scale-up without comparability planning. Programs that wait too long to strengthen CMC foundations are more likely to hit delays later. For that reason, the strongest AAV manufacturing strategy today is one built around early product definition, robust platform design, orthogonal analytics, formulation awareness, and lifecycle planning.

PackGene’s advantage is best expressed as integration (table 1). By combining platform manufacturing logic with analytical support, scalable process design, quality-focused execution, and development-stage awareness, we can help sponsors reduce risk, accelerate decisions, and build stronger AAV CMC packages from early development through clinical readiness. This positions the company to speak directly to the need for a partner that can connect process design, analytical control, manufacturing execution, and regulatory readiness into one coordinated development pathway.

Table 1. PackGene’s platform advantages in AAV manufacturing

Conclusion and Key Takeaways

The path to a successful AAV gene therapy is paved with complex CMC challenges, from vector design and upstream variability to downstream purification hurdles and the demands of a multifaceted analytical strategy. A reactive, piecemeal approach is a recipe for delay and failure. As the industry matures, the adoption of a proactive, integrated, and platform-based CMC strategy is no longer optional—it is a prerequisite for success.

A Practical “Top 10” CMC Checklist for AAV Programs:

1. Define product CQAs early based on the QTPP (route, dose, serotype, MoA).
2. Lock vector genome design with input from CMC teams to ensure manufacturability.
3. Control plasmids and raw materials as critical inputs, prioritizing high supercoiled content.
4. Optimize upstream processes for robustness, linking CPPs to CQAs, not just peak titer.
5. Design DSP around impurity clearance, with a focus on orthogonal separation methods for full/empty capsids.
6. Employ an orthogonal analytical panel that accurately measures capsid content, genome integrity, and aggregation.
7. Build a matrix potency assurance strategy that is linked to the product’s MoA.
8. De-risk formulation and fill-finish early with forced degradation and container compatibility studies.
9. Plan comparability from the start, retaining representative lots and defining a change-control protocol.
10. Integrate CMC, analytics, QA, regulatory, and CDMO execution from day one in a seamless partnership.

By adhering to these principles and partnering with a fully integrated CDMO like PackGene, sponsors can transform CMC from a development hurdle into a competitive advantage, securing a more predictable and efficient path to delivering safe and effective therapies to the patients who need them most.

Author: Jin Qiu

References

1. Kowshik, N. C. S. S., & Singh, P. (2025). Advancing AAV vector manufacturing: challenges, innovations, and future directions for gene therapy. Frontiers in Molecular Medicine, 5, 1709095.
2. Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021). Manufacturing challenges and rational formulation development for AAV viral vectors. Journal of Pharmaceutical Sciences, 110(7), 2609-2624.
3. Jiang, Z., & Dalby, P. A. (2023). Challenges in scaling up AAV-based gene therapy manufacturing. Trends in Biotechnology.
4. Dobrowsky, T., Gianni, D., Pieracci, J., & Suh, J. (2021). AAV manufacturing for clinical use: Insights on current challenges from the upstream process perspective. Current Opinion in Biomedical Engineering, 20, 100353.
5. Wright, J. F. (2008). Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Therapy, 15(11), 840-848.
6. Smith, D. C. (n.d.). AAV Vector Manufacturing – Challenges & Opportunities in the Manufacturing of AAV Vectors Used in the Delivery of Gene Therapy Treatments. Drug Development & Delivery.
7. Holt, A. (2021, March 27). Platform Development in AAV Manufacturing: Cost and Timeline Impact on Clinical Development. American Pharmaceutical Review.
8. Le Bec, C. (2021). Gene therapy CMC and quality control. Cell & Gene Therapy Insights, 7(9), 1239-1241.
9. U.S. Food and Drug Administration. (2020). Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs).
10. U.S. Food and Drug Administration. (2023, draft). Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products.
11. U.S. Food and Drug Administration. (2023, draft). Potency Assurance for Cellular and Gene Therapy Products.
12. EMA/ICH. (2019). ICH Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin.
13. Gimpel, A. L., et al. (2021). Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies. Molecular Therapy Methods & Clinical Development, 20, 740-754.